Our investment in Hertility

We are living in an infertility crisis where 1 in 7 couples are infertile.

Hertility gives women the opportunity to proactively learn about their fertility earlier (this usually happens after trying for 12 months unsuccessfully or having 2 miscarriages), enabling women to make informed decisions about their future.

Hertility is an approved Care Quality Commission provider, regulatory approval which means they have incredible scope to offer full end to end diagnostics and prescriptions.

To date, they’ve developed an at-home blood test, paired with bespoke testing, actionable advice and a route-to-care.

They tailor each woman’s individual hormone panel by taking into account her reproductive and medical history, ensuring that testing, route-to-diagnosis and care is personalised, accurate, accessible and affordable.

2020 really catapulted at-home testing into a category of essential medical technology, and one which we believe is here to stay.

They have a UK-wide ongoing clinical trial which will further enable them to detect risk of developing reproductive conditions, as well as detecting early warning signs.

And employers? Yes, an exciting opportunity that Hertility is driving is via employers. My partner Emma wrote this article as to why employers should improve benefits through the reproductive journey.

But as always, it was the team we fell in love with first and foremost: Dr Helen, molecular geneticist and a world leading expert on reproductive science, Dr Natalie, ovarian biologist with expertise in bringing scientific discovery to clinical practice and Deirdre, former lawyer developing the company’s growth engine.

And we’re delighted to partner with Mark at Venrex again, with fantastic angels joining the round including Matt Robinson (Founder of Nested and GoCardless), Evelyn Bourke (ex CEO of BUPA), Emma Burrows (Head of Engineering at Stripe).